MMR Vaccine Side Effects (Measles, Mumps & Rubella — What VAERS & Lareb Report)

1. Basic Information

Diseases Protected Against

• Measles — Airborne viral illness; characterized by high fever, cough, coryza, conjunctivitis, and a maculopapular rash. Complications include pneumonia, otitis media, encephalitis (1 per 1,000 cases), and subacute sclerosing panencephalitis (SSPE, ~4–11 per 100,000 cases). Case-fatality rate in developed countries: ~1–3 per 1,000 cases.
• Mumps — Viral illness causing parotitis; complications include orchitis (in ~25% of post-pubertal males), oophoritis, aseptic meningitis, and sensorineural hearing loss.
• Rubella — Generally mild viral illness with rash and lymphadenopathy. Primary concern is congenital rubella syndrome (CRS) when infection occurs during pregnancy, causing deafness, heart defects, cataracts, and developmental disability in the fetus.

CDC Recommended Schedule (United States, 2025)

Source: CDC Advisory Committee on Immunization Practices (ACIP), 2025 Child & Adolescent Immunization Schedule.

Licensed Products (U.S.)

• M-M-R^® II (Merck & Co.) — Licensed 1978. Contains live attenuated measles (Enders' attenuated Edmonston strain), mumps (Jeryl Lynn strain), and rubella (Wistar RA 27/3 strain).
• PRIORIX (GlaxoSmithKline) — Licensed in the U.S. June 2022. Contains live attenuated measles (Schwarz strain), mumps (RIT 4385 strain, derived from Jeryl Lynn), and rubella (Wistar RA 27/3 strain).
• ProQuad^® (MMRV) — MMR + varicella combination. Not reviewed separately on this page; safety signals differ (see Section 4).

Documented Adverse Events (HRSA VICP)

The following adverse events are documented by the HRSA Vaccine Injury Compensation Program (VICP) as having a temporal relationship to this vaccine. These are not necessarily confirmed causal relationships, but rather conditions for which claims have been compensated or are presumed caused by the vaccine.

Ingredients (Package Insert)

Structured composition for 2 branded products covered on this page, taken from FDA-approved package inserts (DailyMed / manufacturer prescribing information). Lists are per product — formulations differ by manufacturer and presentation. Click an ingredient name to open its safety-context page when available.

Causality assessment & potential mechanisms

Conditions below combine WHO-style causality levels with potential biological mechanisms from the site mechanism catalog (ae_mechanisms_catalog.json). HRSA VICP table listing (where shown) indicates a compensable temporal association under U.S. program rules — not automatic proof of causation for every case. Mechanisms are hypothesis-level pathways with graded evidence.

Framework: WHO causality + HRSA VICP (where applicable) + AE mechanism catalog. Last updated: 2026-07-18. Schema: schemas/vaccine_injury_table.schema.json · Mechanisms: schemas/ae_mechanism.schema.json. Not medical or legal advice.

2. Pre-Licensure Clinical Trial Data

M-M-R^® II (Merck) — Pivotal Trials

The original MMR vaccine (M-M-R) was licensed in 1971; M-M-R^® II (with a more stabilised rubella component) was licensed in 1978. The pivotal pre-licensure trials for M-M-R^® II enrolled approximately 1,964 children across multiple studies, principally evaluating immunogenicity (seroconversion rates).

PRIORIX (GSK) — Pivotal Trials for U.S. Licensure (2022)

PRIORIX was licensed in the U.S. based on six clinical trials that included a total of ~6,449 participants who received PRIORIX. The trials were conducted in multiple countries. Three studies compared PRIORIX to M-M-R^® II. The primary immunogenicity endpoints were non-inferiority comparisons of seroresponse rates and geometric mean titers.

• Total PRIORIX recipients in safety population: ~6,449 (children 12 months – 6 years, plus a smaller adult cohort)
• Safety follow-up duration: 42 days for systemic adverse events; serious adverse events (SAEs) collected for 6 months
• Non-inferiority met for all three antigens vs. M-M-R^® II

Most Common Adverse Reactions (Pre-Licensure Trials)

Sources: M-M-R^® II and PRIORIX prescribing information / FDA review documents. Frequencies vary by trial design, age group, and case definitions used.

Key Limitations of Pre-Licensure Trial Data

• Sample size: Pre-licensure trials are powered to detect common adverse events and demonstrate immunogenicity, not to detect rare but serious adverse events (e.g., those occurring at rates < 1 per 10,000 doses).
• Follow-up duration: Safety follow-up was limited to 42 days in most protocols, meaning long-term or delayed-onset adverse events could not be assessed.
• Exclusion criteria: Trials excluded children with significant pre-existing medical conditions, immunodeficiencies, and known allergies, limiting generalizability to those subpopulations.
• Demographics: Trial populations were not always fully representative of the demographic diversity of the U.S. population (particularly true for the older M-M-R^® II trials conducted in the 1970s).
• No placebo arm: Most MMR trials used active comparators or open-label designs. True placebo-controlled data are limited.

3. Post-Licensure Safety Data

Vaccine Safety Datalink (VSD)

The VSD is a collaboration between the CDC and integrated healthcare organizations that monitor the electronic health records of approximately 9–10 million people annually (~3% of the U.S. population). It enables near-real-time active surveillance ("rapid cycle analysis") as well as retrospective cohort and case-control studies.

• Design: Active surveillance using electronic health records; includes both self-controlled case series analyses and cohort studies.
• Key VSD findings for MMR:
  • Febrile seizures: Consistently observed increased risk in the 5–12 day window after MMR vaccination. VSD estimates: ~1 additional febrile seizure per 2,300–3,000 doses in children aged 12–23 months. Risk is higher with MMRV (ProQuad) compared to MMR + varicella given separately (~1 per 1,250 MMRV doses).
  • ITP (Immune Thrombocytopenic Purpura): VSD self-controlled risk-interval analyses estimated approximately 1 case per 30,000–40,000 MMR doses in the 6-week post-vaccination window.
  • Autism: Multiple large VSD cohort and case-control studies have not found an increased risk. The largest VSD study on this question (2004, DeStefano et al.) included >250,000 children.
  • No association found: VSD studies have not identified statistically significant associations between MMR and ataxia, encephalopathy, or type 1 diabetes.

Sources: DeStefano et al. (2004) Pediatrics; Klein et al. (2010) Pediatrics; VSD annual surveillance reports (CDC).

VAERS (Vaccine Adverse Event Reporting System)

VAERS is a passive (spontaneous) reporting system co-managed by the CDC and FDA. VAERS cannot establish causation. Reports may be submitted by anyone and reflect unverified temporal associations. Underreporting is common; conversely, stimulated reporting can occur after media attention.

Major Independent Post-Licensure Reviews

The Wakefield Paper (1998) and Subsequent Investigation

A 1998 case series (n=12) by Wakefield et al., published in The Lancet, hypothesised an association between MMR, gastrointestinal disease, and autism. The paper was fully retracted by The Lancet in 2010 following a General Medical Council (UK) investigation that found Wakefield guilty of serious professional misconduct, including ethical violations and undisclosed financial conflicts of interest. Multiple large-scale epidemiological studies (see Section 6 and References) have since found no evidence of an association. This is noted here because the Wakefield paper was the primary origin of the MMR–autism hypothesis and continues to influence public perception despite retraction.

Confirmed Safety Signals Identified in Post-Licensure Data

• Febrile seizures — Observed in VSD, VAERS, and multiple international databases. Risk window: 5–12 days post-vaccination (coinciding with peak viremia from measles component).
• Immune Thrombocytopenic Purpura (ITP) — Signal identified through VSD and confirmed in multiple international studies. Typically transient and self-limited.
• Measles Inclusion Body Encephalitis (MIBE) — Rarely reported in severely immunocompromised individuals; confirmed causal by IOM.
• Febrile seizures at a higher rate with MMRV (ProQuad) compared to MMR + varicella given separately — Identified through VSD rapid cycle analysis, confirmed in post-marketing studies.

Note: Safety "signals" identified through post-licensure surveillance require further analytical epidemiological studies to confirm or refute causality. Signals may later be determined to be coincidental.

VAERS Reporting Data — Halma & Varon (2025), DARE-SAFE

The DARE-SAFE paper (Halma & Varon, Pharmacoepidemiology 2025, CC BY 4.0) analyzed VAERS reports for vaccines administered in the United States from 2006–2022. The following data are extracted from Table 1 of that paper for this vaccine (MMR combined (Measles, Mumps, Rubella; M-M-R II + PRIORIX)):

Source: Halma, M.; Varon, J. DARE-SAFE. Pharmacoepidemiology. 2025. DOI: 10.3390/pharma4020007. CC BY 4.0. Data from Table 1.

4. Documented Adverse Events — Evidence of Association

▶ Adverse Events with Strong Evidence of Causal Association

Criteria: Consistent epidemiological data from multiple independent studies, supported by mechanistic plausibility, and reviewed by IOM / NASEM or equivalent authoritative body.

• Febrile seizures: Occurring at an estimated rate of ~1 per 2,300–3,000 doses in the 5–12 day post-vaccination window (MMR alone). Risk is elevated with MMRV (~1 per 1,250 doses). Most febrile seizures are self-limited and do not cause long-term neurological sequelae. Strong
• Immune Thrombocytopenic Purpura (ITP): Estimated at ~1 per 30,000–40,000 doses, typically within 6 weeks of vaccination. Usually transient; resolves spontaneously or with treatment in the majority of children. The risk is lower than the risk of ITP following natural measles or rubella infection. Strong
• Anaphylaxis: Estimated at 1–3 per million doses. Attributed to vaccine excipients (e.g., gelatin, neomycin). Standard contraindication for individuals with known severe allergic reaction to a prior dose or vaccine component. Strong
• Measles Inclusion Body Encephalitis (MIBE): Documented in severely immunocompromised individuals (e.g., those with advanced HIV, congenital immunodeficiency). Extremely rare. Strong
• Transient arthralgia / arthritis: Associated with the rubella component (RA 27/3 strain). Reported in ~10–25% of susceptible adult women vaccinated post-puberty; usually mild and self-limited. Much less common in children. Strong
• Parotitis / lymphadenopathy: Mild, transient swelling of parotid gland or lymph nodes, attributable to the mumps and rubella vaccine virus components respectively. Strong

▶ Adverse Events with Moderate or Preliminary Evidence

Criteria: Some epidemiological evidence consistent with a signal, but data are limited by sample size, inconsistent findings across studies, or insufficient mechanistic evidence.

• Aseptic meningitis: Associated with older mumps vaccine strains containing the Urabe Am9 strain (not used in the U.S.). The Jeryl Lynn and RIT 4385 strains used in U.S.-licensed MMR vaccines have not been consistently associated with aseptic meningitis. Residual evidence is considered insufficient to rule out a very rare association. Moderate (for Urabe strain; Limited for Jeryl Lynn / RIT 4385)
• Encephalopathy / encephalitis (in immunocompetent individuals): Case reports exist but large-scale epidemiological studies have not consistently demonstrated an association beyond background rates. IOM (2012) concluded that evidence "favors rejection" of a causal relationship for MMR and encephalopathy in immunocompetent individuals, but noted some evidence for a rare association with encephalitis in immunocompromised. Preliminary
• Guillain-Barré Syndrome (GBS): Isolated case reports exist; no consistent signal in large epidemiological studies. IOM (2012) concluded evidence is inadequate to accept or reject a causal relationship. Limited
• Chronic arthropathy: Some studies have suggested a possible association between rubella vaccination and persistent joint symptoms, but evidence is inconsistent. IOM determined the evidence was inadequate. Preliminary

▶ Published Evidence Does Not Support a Causal Association

Criteria: Multiple large, well-controlled epidemiological studies have consistently failed to find an association; IOM / NASEM has rejected a causal relationship; or the preponderance of high-quality evidence is against an association.

• Autism Spectrum Disorder (ASD): Evidence against a causal association is extensive. Major studies include:
  • Danish nationwide cohort (Hviid et al., 2019): N=657,461; HR 0.93 (95% CI 0.85–1.02)
  • VSD case-control study (DeStefano et al., 2004): N > 250,000
  • Japanese cohort study (Honda et al., 2005): N=31,426; no MMR–ASD association
  • UK case-control study (Smeeth et al., 2004): N=1,294 ASD cases; OR 0.86 (95% CI 0.68–1.08)
  • Canadian cohort (Fombonne et al., 2006): N=27,749
  • Meta-analysis (Taylor et al., 2014): 10 studies, >1.2 million children; no association
  The IOM (2012) concluded: "The evidence favors rejection of a causal relationship between MMR vaccine and autism." No Association
• Type 1 Diabetes Mellitus: Multiple cohort and case-control studies, including a 10-year Danish cohort of >700,000 children, have not found an association. IOM (2012) favored rejection of causality. No Association
• Inflammatory Bowel Disease (IBD): Studied extensively following the Wakefield hypothesis; multiple large epidemiological studies have not found an association. IOM rejected causality. No Association
• Asthma: Several large cohort studies have not identified an association. IOM (2012) favored rejection of causality. No Association
• Multiple Sclerosis: No consistent epidemiological evidence for an association. No Association
• Leukemia: Multiple studies have not identified an association. Some studies have suggested MMR may be associated with a reduced risk of childhood leukemia, though this finding is not consistent. No Association

5. Disease Prevention Benefits

5a. Measles — Pre-Vaccine vs. Post-Vaccine Era (United States)

Source: CDC MMWR surveillance summaries; CDC Pink Book (Measles chapter). Reported cases underestimate true incidence; pre-vaccine era case estimates are ~10x higher than reported cases because measles was ubiquitous.

5b. Mumps — Pre-Vaccine vs. Post-Vaccine Era (United States)

Source: CDC MMWR; CDC Pink Book (Mumps chapter). Note: Mumps outbreaks continue to occur in highly vaccinated populations, particularly in close-contact settings (colleges, sports teams), likely due to waning immunity and less-than-perfect 2-dose effectiveness (~88%, range 79–95%).

5c. Rubella and Congenital Rubella Syndrome — Pre-Vaccine vs. Post-Vaccine Era (United States)

Source: CDC Pink Book (Rubella chapter); PAHO rubella elimination declaration (2015).

Current Disease Burden & Outbreak Context

• Measles: As of 2024–2025, the U.S. has experienced a resurgence of measles cases linked to international importation, primarily affecting unvaccinated individuals and communities with suboptimal vaccination coverage. The CDC reported over 280 cases in the first quarter of 2025 alone — exceeding the total for any full year since 2019. Most cases (>90%) occurred in unvaccinated persons or persons with unknown vaccination status.
• Mumps: Sporadic outbreaks continue, predominantly in vaccinated populations in high-density settings. The 2-dose MMR series has an estimated effectiveness against mumps of ~88% (range across studies: 79–95%), lower than the >95% observed in pre-licensure serological studies — attributed to waning immunity over time and potential antigenic differences between vaccine and circulating wild-type strains.
• Rubella: Endemic transmission has been interrupted in the U.S. since 2015, and no U.S.-acquired CRS cases have been reported since 2012. Imported cases continue to be detected occasionally.

Disease Burden Over Time

Reported U.S. disease burden by year. The dashed vertical line marks vaccine introduction. Hover or tap data points for values; use arrow keys when a chart has focus.

7. International Surveillance & Global Data

Quick links to public pharmacovigilance databases and trial registries relevant to MMR Vaccine. Reporting counts do not establish causality.

8. Curated Adverse Event Literature

Curated peer-reviewed literature linking specific adverse events to MMR Vaccine. Each entry is a case report, case series, or related safety publication identified via PubMed. Expand Search PubMed for additional literature below to run custom queries.

9. Key References

References are organised by category. Links are provided to the original source where available.

Pre-Licensure Trials / FDA Review Documents

1. Merck & Co., Inc. M-M-R^® II (Measles, Mumps, and Rubella Virus Vaccine Live) — Prescribing Information. merck.com/product/usa/pi_circulars/m/mmr_ii/mmr_ii_pi.pdf
2. GlaxoSmithKline. PRIORIX (Measles, Mumps, and Rubella Vaccine, Live) — Prescribing Information. gskpro.com
3. FDA. Clinical Review — PRIORIX (BLA 125759), 2022. fda.gov/vaccines-blood-biologics/vaccines/priorix

Systematic Reviews & Meta-Analyses

4. Demicheli V, Rivetti A, Debalini MG, Di Pietrantonj C. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews. 2012 (updated 2020). DOI: 10.1002/14651858.CD004407.pub3
5. Taylor LE, Swerdfeger AL, Eslick GD. Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine. 2014;32(29):3623–3629. DOI: 10.1016/j.vaccine.2014.04.085
6. Pietrantonj CD, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2020. DOI: 10.1002/14651858.CD004407.pub4

Institute of Medicine / National Academies Reports

7. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Washington, DC: The National Academies Press; 2012. nationalacademies.org
8. Committee on the Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule. The Childhood Immunization Schedule and Safety: Stakeholder Concerns, Scientific Evidence, and Future Studies. National Academies Press; 2013.

Major Post-Licensure Observational Studies

9. Hviid A, Hansen JV, Frisch M, Melbye M. Measles, Mumps, Rubella Vaccination and Autism — A Nationwide Cohort Study. Annals of Internal Medicine. 2019;170(8):513–520. DOI: 10.7326/M18-2101
10. DeStefano F, Bhasin TK, Thompson WW, et al. Age at first measles-mumps-rubella vaccination in children with autism and school-matched control subjects. Pediatrics. 2004;113(2):259–266. DOI: 10.1542/peds.113.2.259
11. Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1–e8. DOI: 10.1542/peds.2010-0665
12. Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics. 2006;118(1):e139–e150. DOI: 10.1542/peds.2005-2993
13. Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. The Lancet. 2004;364(9438):963–969. DOI: 10.1016/S0140-6736(04)17020-7
14. France EK, Smith-Raymond L, Xu S, et al. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children. Pediatrics. 2008;121(3):e687–e692. DOI: 10.1542/peds.2007-1578

Official Surveillance and Public Health References

15. CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book) — Measles, Mumps, Rubella chapters. cdc.gov/pinkbook
16. CDC. Vaccine Safety Datalink (VSD). cdc.gov/vaccine-safety/about/vsd.html
17. CDC/FDA. Vaccine Adverse Event Reporting System (VAERS). vaers.hhs.gov
18. CDC. 2025 Child & Adolescent Immunization Schedule. cdc.gov/vaccines/hcp/imz-schedules
19. CDC. Measles Cases and Outbreaks (current surveillance). cdc.gov/measles/data-research
20. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. The Lancet. 1998;351(9103):637–641. RETRACTED (2010). DOI: 10.1016/S0140-6736(97)11096-0 (retracted)
21. Halma, M.; Varon, J. DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines. Pharmacoepidemiology. 2025, 4, 7. DOI: 10.3390/pharma4020007. CC BY 4.0.